The Biotech That Did Everything Right and Still Couldn't Survive

It's the kind of work that sounds genuinely promising. The founders had more than 30 years of research behind the target. But "promising" and "fundable" are two very different words in 2026.

Mineva said the team was "convinced that ADAM8-targeted therapies and diagnostics have future value." The company's website now says the intellectual property is being transferred back to the original inventors, who are open to licensing, acquisition, or collaboration. In other words: the science is homeless, and it's looking for a new address.

The Investor Math That Killed Adecto

Adecto's problem wasn't unique. It was a symptom of a broader disease infecting early-stage biotech.

Today's investors want de-risked assets. They want clinical data, regulatory milestones, or at least a clear path to human trials before writing checks. A preclinical company targeting a novel protein that hasn't been tested in humans? That's like asking someone to bet on a horse that hasn't been born yet.

The numbers tell the story clearly. Seed and Series A rounds in biotech fell from 228 deals in 2024 to just 191 in 2025. First financings for biotech startups collapsed from $2.6 billion in Q1 2025 to just $900 million in Q2 2025, the lowest total in five quarters.

Early-stage biopharma's share of total funding has been shrinking for years, falling from 44% to 32% since 2020. There's money out there, but it's flowing to later-stage programs with human proof of concept. If you're preclinical with a novel target, you're essentially invisible.

The Rich Get Richer, the Small Get Buried

What makes this especially frustrating is that the top of the biotech food chain has never looked healthier. Big pharma is on an acquisition spree in 2026, with numerous transactions clearing the billion-dollar mark. Multiple deals have landed in the $5 billion to $15 billion range. Patent cliffs are approaching, pipelines need replenishing, and large companies have the cash to go shopping.

But that M&A frenzy isn't trickling down to early-stage startups the way you might expect. JPMorgan found that upfront cash in licensing deals represented only 6% of total deal value this year. The rest is milestone payments: money that arrives later, if it arrives at all. That's not a lifeline for a company like Adecto that needs cash now to keep the lights on.

It's like watching a luxury car dealership thrive while the used car lot across the street goes bankrupt. Same industry, completely different realities.

Adecto Isn't Alone

The shutdown tracker for 2026 reads like a memorial wall. Crunchbase reported that Q1 2026 saw 2.6 times more company closures than Q1 2025. f5 Therapeutics, another early-stage biotech, shut down after six years; its founder called conditions for young platforms the worst in memory. Nido Biosciences folded after a Phase 2 miss. Kezar Life Sciences crumbled under FDA delays and investor pressure.

A Foley report found that 2026 has seen more venture-backed shutdowns than any point on record, with the largest share coming from companies founded between 2019 and 2021. Those were the years when money was cheap, valuations were generous, and everyone believed the next breakthrough was just one funding round away. Now the bill has come due.

What This Really Means

Adecto's closure isn't just a business story. It's a science story, and a troubling one.

The biotech funding model is supposed to work like a conveyor belt. Basic research produces promising targets. Startups pick them up, develop them, and eventually hand them off to larger companies that can run expensive clinical trials. When the conveyor belt breaks at the early stage, those targets don't just pause; they can disappear entirely.

Adecto's ADAM8 work is technically still alive: the IP goes back to the inventors, and they're looking for partners. But anyone who's watched orphaned biotech assets knows how this usually plays out. Without a dedicated team and funding, promising science tends to gather dust on a shelf.

The biotech industry loves to celebrate its mega-deals and billion-dollar acquisitions. And those deals matter. But every time a company like Adecto shuts down, we should ask an uncomfortable question: how many future breakthroughs are dying in the funding gap between a great idea and a first human dose?

We'll probably never know. And that might be the most unsettling part of all.

Amgen's $28 Billion Bet on Horizon Just Got a Whole Lot Smarter

Amgen's $27.8 billion Horizon Therapeutics acquisition just delivered its biggest pipeline surprise yet. A fusion protein that blocks immune cell crosstalk passed its first pivotal trial in Sjögren's disease, a condition with zero approved treatments, and the implications for Amgen's autoimmune franchise are massive.